|
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
|
Written by: J. Smith |
Hits: 525
|
|
Signos Press Release Raises Questions About FDA Clearance Claims
|
Written by: J. Smith |
Hits: 592
|
|
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
|
Written by: J. Smith |
Hits: 841
|
|
FDA Approves Wegovy for MASH Treatment
|
Written by: J. Smith |
Hits: 553
|
|
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
|
Written by: J. Smith |
Hits: 601
|
|
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
|
Written by: J. Smith |
Hits: 451
|
|
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
|
Written by: J. Smith |
Hits: 675
|
|
Genetic Test Predicts Obesity Risk in Early Childhood
|
Written by: J. Smith |
Hits: 524
|
|
Novo Nordisk Ends Partnership with Hims & Hers Over Safety Concerns
|
Written by: J. Smith |
Hits: 435
|
|
Lilly’s Once-Daily Oral GLP-1 Pill Shows Promise for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 723
|
